Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 1,869 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: Osteoarthritis
Interventions: OA-PCP Intervention, Attention Control; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 65 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Neuralgia, Postherpetic
Interventions: GEn 1200mg/day, GEn 3600mg/day; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 42
States / cities: Phoenix, Arizona • Oxnard, California • Roseville, California + 36 more

Conditions: Multiple Sclerosis, Hypertension
Interventions: Home-based aerobic training; Behavioral
Lead sponsor: University of Massachusetts, Boston; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cigarette Smoking
Interventions: Standard Treatment, Behavioral Activation Treatment for Smoking, Transdermal Nicotine Patch; Behavioral · Drug
Lead sponsor: University of Maryland, College Park; Other
Eligibility: 18 Years to 65 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: College Park, Maryland

Conditions: Primary Mitochondrial Disease
Interventions: Elamipretide, Placebo; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 4
States / cities: San Diego, California • Boston, Massachusetts • Akron, Ohio + 1 more

Conditions: Healthy, Hepatitis C, Chronic
Interventions: TG-2349, placebo; Drug
Lead sponsor: TaiGen Biotechnology Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Cypress, California

Conditions: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions: Ravulizumab; Biological
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 10
States / cities: Aurora, Colorado • Fort Collins, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Glioblastoma Multiform (Grade IV Astrocytoma)
Interventions: PolyMVA; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years to 79 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Hypercholesterolemia
Interventions: Evolocumab, Standard of care; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 78
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 66 more

Conditions: Low Back Pain
Interventions: Progressive Muscle Relaxation (PMR), Clinical Massage Therapy (CMT); Behavioral · Procedure
Lead sponsor: William G Elder JR; Other
Eligibility: 21 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: High Blood Pressure, Liver Transplant, Renal Function Abnormal
Interventions: Amlodipine Besylate, Chlorthalidone; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Perennial Allergic Rhinitis
Interventions: ciclesonide hydrofluoroalkane (HFA) nasal aerosol, mometasone nasal inhalation; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 6
States / cities: Mission Viejo, California • San Diego, California • North Dartmouth, Massachusetts + 3 more

Conditions: Hormone Receptor Positive Metastatic Breast Cancer
Interventions: Exercise Treatment; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 19 Years and older · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 10
States / cities: Indianapolis, Indiana • Baltimore, Maryland • Basking Ridge, New Jersey + 7 more

Conditions: Sickle Cell Disease
Interventions: Aes-103, Placebo; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Stress, Fatigue, Anxiety
Interventions: Massage; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy Volunteers
Interventions: Vonoprazan ODT-1 or ODT-2 without Water, Vonoprazan ODT-1 or ODT-2 with Water, Vonoprazan (Reference); Drug
Lead sponsor: Phathom Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Diabetes Mellitus, Coronary Artery Disease
Interventions: Prasugrel, Ticagrelor; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 74 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Phenylketonuria
Interventions: Pegvaliase, Methotrexate; Biological · Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 12
States / cities: Los Angeles, California • Aurora, Colorado • Tampa, Florida + 9 more

Conditions: Metabolic Syndrome
Interventions: Professional nutrition counseling, No professional nutrition counseling; Other
Lead sponsor: Madigan Army Medical Center; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Complex Regional Pain Syndrome Type I, Complex Regional Pain Syndrome Type II
Interventions: Placebo, Neurotropin; Drug
Lead sponsor: National Institute of Nursing Research (NINR); NIH
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Knee Osteoarthritis
Interventions: Noxious Electrical Stimulation (NxES); Device
Lead sponsor: University of New England; Other
Eligibility: 50 Years to 90 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Portland, Maine

Conditions: Parkinson Disease
Interventions: Nordic walking exercise; Other
Lead sponsor: Grand Valley State University; Other
Eligibility: 21 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Advanced or Metastatic Melanoma
Interventions: Nivolumab, Ipilimumab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 11
States / cities: Tampa, Florida • Indianapolis, Indiana • Boston, Massachusetts + 4 more

Conditions: Engagement, Patient, First Episode Psychosis
Interventions: Behavioral Activation for First Episode Psychosis, Treatment As Usual; Behavioral
Lead sponsor: California State University, San Bernardino; Other
Eligibility: 15 Years to 35 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Granada Hills, California • Sylmar, California

Search by objective public record fields.

Physical Activity Pathway for Patients With Osteoarthritis in Primary Care (OA-PCP) (R33)

A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment

Vascular Mechanisms, Functional Outcomes, & Exercise Among Persons With Multiple Sclerosis With Hypertension

Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms

Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study

A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA

Open Label Study of Long Term Evaluation Against LDL-C Trial

Chronic Low Back Pain and Primary Health Care

Mechanism of Hypertension Treatments in Liver Transplant Recipients (BLOCK LTR-HTN)

Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis

Exercise Treatment With Standard Therapy for Metastatic Breast Cancer

A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease

Measuring the Effect of Therapeutic Massage on Pain and Discomfort in Cardiac Cath Lab Staff

A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants

Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes

Immune Modulation During Palynziq® Treatment in Adults (IMPALA)

Precision Nutrition Impact on Health-Related Behavior Change

Neurotropin to Treat Chronic Neuropathic Pain

Influence of Noxious Electrical Stimulation on Chronic Pain From Knee Osteoarthritis

Effects of Nordic Walking Exercise on Gait, Motor/Non-motor Symptoms, and Exercise Biomarkers in Parkinson's Disease

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)

Optimizing Engagement in Services for First-Episode Psychosis